Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Thioredoxin reductase | 0.013 | 1 | 1 |
Plasmodium falciparum | glutathione reductase | 0.013 | 1 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0045 | 0.0195 | 0.5 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.013 | 1 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.013 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Loa Loa (eye worm) | thioredoxin reductase | 0.013 | 1 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0045 | 0.0195 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0045 | 0.0195 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.013 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.013 | 1 | 1 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0045 | 0.0195 | 0.0195 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0045 | 0.0195 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.013 | 1 | 1 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0045 | 0.0195 | 0.0195 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0045 | 0.0195 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.013 | 1 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0045 | 0.0195 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0045 | 0.0195 | 0.5 |
Treponema pallidum | NADH oxidase | 0.0045 | 0.0195 | 0.5 |
Leishmania major | trypanothione reductase | 0.013 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0045 | 0.0195 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.013 | 1 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0045 | 0.0195 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.013 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Loa Loa (eye worm) | glutathione reductase | 0.013 | 1 | 0.5 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0045 | 0.0195 | 0.0195 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.013 | 1 | 1 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0045 | 0.0195 | 0.0195 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0045 | 0.0195 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.